CEO SUMMARY: CMS and its contractors had ample opportunity to implement a new reimbursement system but failed to act in a timely manner, stated an expert familiar with the problem. The result is that laboratories, particularly those that have one or two proprietary molecular tests, are being harmed needlessly, he said. Without regular payments for […]
How CMS ‘Mismanaged’ Pricing of Molecular Tests
Critic says actions by CMS and its contractors are harming smaller labs that run molecular tests
- By Joseph Burns
- > From the Volume XX No. 5 - April 15, 2013 Issue
- Tags: cap, clinical lab, Clinical Laboratory, clinical laboratory industry, clinical labs, dark report, diagnostic lab, diagnostic laboratories, diagnostic testing, Diagnostic tests, impac, lab test, lab testing, lab testing companies, laboratories, laboratory company, laboratory industry, laboratory organization, laboratory organizations, medical diagnostic, Medicare, molecular diagnostic, molecular diagnostic companies, molecular tests, mopath, private payer, revenue cycle, revenue cycle management, the clinical laboratory, the dark report, xifin
